Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ASND NASDAQ:BBIO NASDAQ:IONS NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.32$21.82$19.69▼$28.35$4.34B0.841.56 million shs7.37 million shsASNDAscendis Pharma A/S$260.75$232.43$160.86▼$271.89$16.26B0.39891,778 shs4.45 million shsBBIOBridgeBio Pharma$70.24$68.88$41.80▼$84.94$13.76B0.984.01 million shs27.06 million shsIONSIonis Pharmaceuticals$81.18$75.03$39.37▼$86.74$13.42B0.371.87 million shs3.83 million shsRAREUltragenyx Pharmaceutical$30.77$24.87$18.29▼$42.37$3.03B0.372.63 million shs17.18 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+17.11%+16.90%+20.17%+14.47%ASNDAscendis Pharma A/S0.00%+12.96%+16.35%+19.42%+51.41%BBIOBridgeBio Pharma0.00%+5.99%+6.01%+1.27%+56.58%IONSIonis Pharmaceuticals0.00%+9.53%+6.12%+11.94%+103.97%RAREUltragenyx Pharmaceutical0.00%+12.14%+28.53%+59.43%-15.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.32$21.82$19.69▼$28.35$4.34B0.841.56 million shs7.37 million shsASNDAscendis Pharma A/S$260.75$232.43$160.86▼$271.89$16.26B0.39891,778 shs4.45 million shsBBIOBridgeBio Pharma$70.24$68.88$41.80▼$84.94$13.76B0.984.01 million shs27.06 million shsIONSIonis Pharmaceuticals$81.18$75.03$39.37▼$86.74$13.42B0.371.87 million shs3.83 million shsRAREUltragenyx Pharmaceutical$30.77$24.87$18.29▼$42.37$3.03B0.372.63 million shs17.18 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+17.11%+16.90%+20.17%+14.47%ASNDAscendis Pharma A/S0.00%+12.96%+16.35%+19.42%+51.41%BBIOBridgeBio Pharma0.00%+5.99%+6.01%+1.27%+56.58%IONSIonis Pharmaceuticals0.00%+9.53%+6.12%+11.94%+103.97%RAREUltragenyx Pharmaceutical0.00%+12.14%+28.53%+59.43%-15.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$31.6324.90% UpsideASNDAscendis Pharma A/S 3.00Buy$295.3913.28% UpsideBBIOBridgeBio Pharma 2.83Moderate Buy$92.9032.26% UpsideIONSIonis Pharmaceuticals 2.90Moderate Buy$102.9026.76% UpsideRAREUltragenyx Pharmaceutical 2.82Moderate Buy$59.5693.57% UpsideCurrent Analyst Ratings BreakdownLatest RARE, BBIO, ASND, IONS, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/25/2026IONSIonis Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $130.006/25/2026IONSIonis Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$122.00 ➝ $129.006/24/2026IONSIonis Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$74.00 ➝ $75.006/24/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/17/2026IONSIonis Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$114.00 ➝ $122.006/16/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$106.00 ➝ $96.006/15/2026IONSIonis Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$108.006/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.10B3.96$0.89 per share28.54$7.25 per share3.49ASNDAscendis Pharma A/S$865.78M18.79N/AN/A($2.97) per share-87.79BBIOBridgeBio Pharma$502.08M27.40N/AN/A($10.77) per share-6.52IONSIonis Pharmaceuticals$944M14.21N/AN/A$3.02 per share26.88RAREUltragenyx Pharmaceutical$670M4.52N/AN/A($0.83) per share-37.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.5132.0531.7934.30%9.61%7.07%8/5/2026 (Estimated)ASNDAscendis Pharma A/S-$258M$8.6730.0824.21N/A57.87%N/A-8.37%8/6/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A540.31N/A-124.42%N/A-65.81%8/4/2026 (Estimated)IONSIonis Pharmaceuticals-$381.39M-$2.07N/AN/AN/A-30.91%-58.65%-10.07%8/5/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)Latest RARE, BBIO, ASND, IONS, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million4/29/2026Q1 2026IONSIonis Pharmaceuticals-$0.85-$0.56+$0.29-$0.56$195.57 million$246.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48ASNDAscendis Pharma A/S0.791.000.72BBIOBridgeBio PharmaN/A1.521.48IONSIonis Pharmaceuticals2.754.104.09RAREUltragenyx PharmaceuticalN/A2.021.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%IONSIonis Pharmaceuticals93.86%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%ASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%IONSIonis Pharmaceuticals1.81%RAREUltragenyx Pharmaceutical5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableIONSIonis Pharmaceuticals1,402165.26 million162.27 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableRARE, BBIO, ASND, IONS, and ACAD HeadlinesRecent News About These CompaniesOP Asset Management Ltd Makes New $1.82 Million Investment in Ultragenyx Pharmaceutical Inc. $RARE1 hour ago | marketbeat.comAssenagon Asset Management S.A. Purchases 2,057,951 Shares of Ultragenyx Pharmaceutical Inc. $RAREJune 26 at 3:12 AM | marketbeat.comUltragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease OpportunityJune 21, 2026 | seekingalpha.com56,238 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Flax Pond Capital LLCJune 20, 2026 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. LtdJune 20, 2026 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 19, 2026 | globenewswire.com50,000 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Ishara Investments LPJune 18, 2026 | marketbeat.comEversept Partners LP Takes $7.30 Million Position in Ultragenyx Pharmaceutical Inc. $RAREJune 18, 2026 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Catalio Capital Management LPJune 18, 2026 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of "Moderate Buy" by BrokeragesJune 18, 2026 | marketbeat.com683 Capital Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. $RAREJune 18, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading 8.4% Higher - Should You Buy?June 17, 2026 | marketbeat.comTraders Purchase High Volume of Ultragenyx Pharmaceutical Put Options (NASDAQ:RARE)June 17, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Sees Unusually-High Trading Volume - Should You Buy?June 16, 2026 | marketbeat.comSofinnova Investments Inc. Invests $1.92 Million in Ultragenyx Pharmaceutical Inc. $RAREJune 16, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 1,899 SharesJune 16, 2026 | insidertrades.comSands Capital Management LLC Sells 284,129 Shares of Ultragenyx Pharmaceutical Inc. $RAREJune 15, 2026 | marketbeat.comHere is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip StocksJune 13, 2026 | insidermonkey.comUltragenyx Pharmaceutical Inc. $RARE Stock Holdings Lifted by GW&K Investment Management LLCJune 11, 2026 | marketbeat.comMotley Fool Wealth Management LLC Lowers Position in Ultragenyx Pharmaceutical Inc. $RAREJune 10, 2026 | marketbeat.comLos Angeles Capital Management LLC Sells 60,515 Shares of Ultragenyx Pharmaceutical Inc. $RAREJune 10, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDraining the Tank: Big Oil Runs on FumesBy Jeffrey Neal Johnson | June 17, 2026What IBM's $10-Billion Quantum Project Means For Smaller PlayersBy Nathan Reiff | June 3, 20263 AI Stocks With Moats That Could Outlast Summer VolatilityBy Chris Markoch | June 16, 2026Everpure: AI Storage Uncertainty Overshadows Breakneck GrowthBy Leo Miller | June 10, 20263 Dividend Stocks Under $50 That Pay You to Wait Out InflationBy Chris Markoch | June 12, 2026RARE, BBIO, ASND, IONS, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$25.32 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$25.47 +0.15 (+0.60%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$260.75 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$264.30 +3.55 (+1.36%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$70.24 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$69.94 -0.30 (-0.43%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Ionis Pharmaceuticals NASDAQ:IONS$81.18 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$82.00 +0.82 (+1.01%) As of 05:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Ultragenyx Pharmaceutical NASDAQ:RARE$30.77 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$31.08 +0.31 (+0.99%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
